Literature DB >> 18830264

A role for IFN-lambda1 in multiple myeloma B cell growth.

A J Novak1, D M Grote, S C Ziesmer, V Rajkumar, S E Doyle, S M Ansell.   

Abstract

Multiple myeloma (MM) is a progressive disease that results from dysregulated proliferation of plasma cells. Although, causative factors such as genetic events and altered expression of anti-apoptotic factors have been described in a number of patients, the mechanistic details that drive myeloma development and continued growth of malignant cells remain largely undefined. Numerous growth factors, including interleukin (IL)-6, Insulin-like growth factor-1 and IL-10 have been shown to promote growth of MM cells suggesting a significant role for cytokines in this disease. Interferon (IFN)-lambda1 is a new member of the Class II cytokine family that, similar to IFN-alpha, has been shown to mediate viral immunity. In light of data supporting a role for cytokines in myeloma, we investigated the significance of IFN-lambda1 on myeloma cell biology. Our studies show for the first time that myeloma cells bind to soluble IFN-lambda1, and that IFN-lambda1 induces myeloma cell growth and protects against dexamethasone-induced cell death. Our data also show that IFN-lambda1 induces phosphorylation of STAT1, STAT3 and Erk. Taken together, our results suggest that IFN-lambda1 may regulate myeloma cell biology and could prove to be therapeutically important.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18830264      PMCID: PMC2771776          DOI: 10.1038/leu.2008.263

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  16 in total

1.  Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6.

Authors:  J J Westendorf; G J Ahmann; P R Greipp; T E Witzig; J A Lust; D F Jelinek
Journal:  Leukemia       Date:  1996-05       Impact factor: 11.528

2.  Development of aggressive plasma cell leukaemia under interferon-alpha therapy.

Authors:  J Bladé; A López-Guillermo; D Tassies; E Montserrat; C Rozman
Journal:  Br J Haematol       Date:  1991-11       Impact factor: 6.998

3.  Effects of interferon alpha on myeloma cells: mechanisms of differential responsiveness.

Authors:  D F Jelinek; T Arora
Journal:  Curr Top Microbiol Immunol       Date:  1997       Impact factor: 4.291

4.  IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression.

Authors:  Stephan Brand; Florian Beigel; Torsten Olszak; Kathrin Zitzmann; Sören T Eichhorst; Jan-Michel Otte; Joachim Diebold; Helmut Diepolder; Barbara Adler; Christoph J Auernhammer; Burkhard Göke; Julia Dambacher
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-07-28       Impact factor: 4.052

5.  Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression.

Authors:  D F Jelinek; K M Aagaard-Tillery; B K Arendt; T Arora; R C Tschumper; J J Westendorf
Journal:  J Clin Invest       Date:  1997-02-01       Impact factor: 14.808

6.  Biological activity of interleukins-28 and -29: comparison with type I interferons.

Authors:  Anthony Meager; Kumuthini Visvalingam; Paula Dilger; Donna Bryan; Meenu Wadhwa
Journal:  Cytokine       Date:  2005-07-21       Impact factor: 3.861

7.  Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells.

Authors:  Kathrin Zitzmann; Stephan Brand; Sebastian Baehs; Burkhard Göke; Jennifer Meinecke; Gerald Spöttl; Heinrich Meyer; Christoph J Auernhammer
Journal:  Biochem Biophys Res Commun       Date:  2006-04-24       Impact factor: 3.575

8.  Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells.

Authors:  Z Y Lu; X G Zhang; C Rodriguez; J Wijdenes; Z J Gu; B Morel-Fournier; J L Harousseau; R Bataille; J F Rossi; B Klein
Journal:  Blood       Date:  1995-05-01       Impact factor: 22.113

9.  Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling.

Authors:  Laure Dumoutier; Amel Tounsi; Thomas Michiels; Caroline Sommereyns; Sergei V Kotenko; Jean-Christophe Renauld
Journal:  J Biol Chem       Date:  2004-05-27       Impact factor: 5.157

Review 10.  Interferons, interferon-like cytokines, and their receptors.

Authors:  Sidney Pestka; Christopher D Krause; Mark R Walter
Journal:  Immunol Rev       Date:  2004-12       Impact factor: 12.988

View more
  12 in total

Review 1.  Interferon-λs: special immunomodulatory agents and potential therapeutic targets.

Authors:  Ya-wen Zheng; Hui Li; Jin-pu Yu; Hua Zhao; Shizhen Emily Wang; Xiu-bao Ren
Journal:  J Innate Immun       Date:  2012-11-30       Impact factor: 7.349

Review 2.  IFN-λ cancer immunotherapy: new kid on the block.

Authors:  Ahmed Lasfar; Helen Gogas; Andrew Zloza; Howard L Kaufman; John M Kirkwood
Journal:  Immunotherapy       Date:  2016-07       Impact factor: 4.196

Review 3.  Interferon-λ orchestrates innate and adaptive mucosal immune responses.

Authors:  Liang Ye; Daniel Schnepf; Peter Staeheli
Journal:  Nat Rev Immunol       Date:  2019-06-14       Impact factor: 53.106

Review 4.  Interferon lambda: a new sword in cancer immunotherapy.

Authors:  Ahmed Lasfar; Walid Abushahba; Murugabaskar Balan; Karine A Cohen-Solal
Journal:  Clin Dev Immunol       Date:  2011-12-06

5.  Understanding IFNλ in rheumatoid arthritis.

Authors:  Rik A de Groen; Bi-Sheng Liu; André Boonstra
Journal:  Arthritis Res Ther       Date:  2014-01-21       Impact factor: 5.156

6.  Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance.

Authors:  Jing Pan; Yuanyuan Sun; Ning Zhang; Jianming Li; Fangxin Ta; Wei Wei; Shanshan Yu; Limei Ai
Journal:  Oncol Lett       Date:  2017-07-07       Impact factor: 2.967

Review 7.  The role of IL-29 in immunity and cancer.

Authors:  Noah E Kelm; Ziwen Zhu; Vivi A Ding; Huaping Xiao; Mark R Wakefield; Qian Bai; Yujiang Fang
Journal:  Crit Rev Oncol Hematol       Date:  2016-08-10       Impact factor: 6.312

8.  IFN-λ Modulates the Migratory Capacity of Canine Mammary Tumor Cells via Regulation of the Expression of Matrix Metalloproteinases and Their Inhibitors.

Authors:  Rafał Pingwara; Daria Kosmala; Natalia Woźniak; Arkadiusz Orzechowski; Joanna Mucha
Journal:  Cells       Date:  2021-04-23       Impact factor: 6.600

9.  Prognosis Relevance of Serum Cytokines in Pancreatic Cancer.

Authors:  Carolina Torres; Ana Linares; Maria José Alejandre; Rogelio J Palomino-Morales; Octavio Caba; Jose Prados; Antonia Aránega; Juan R Delgado; Antonio Irigoyen; Joaquina Martínez-Galán; Francisco M Ortuño; Ignacio Rojas; Sonia Perales
Journal:  Biomed Res Int       Date:  2015-08-04       Impact factor: 3.411

10.  Antitumor potential of a synthetic interferon-alpha/PLGF-2 positive charge peptide hybrid molecule in pancreatic cancer cells.

Authors:  Hongmei Yin; Naifei Chen; Rui Guo; Hong Wang; Wei Li; Guanjun Wang; Jiuwei Cui; Haofan Jin; Ji-Fan Hu
Journal:  Sci Rep       Date:  2015-11-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.